Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents
Shunan Wang, Xingtong Wang, Mingsuo Liu, et al.
Annals of Hematology (2018) Vol. 97, Iss. 4, pp. 563-572
Closed Access | Times Cited: 21

Showing 21 citing articles:

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia‐Manero, et al.
Blood Advances (2022) Vol. 6, Iss. 10, pp. 3027-3035
Open Access | Times Cited: 28
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy
Nathaniel R. Wilson, Marina Konopleva, Joseph D. Khoury, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 11, pp. 734-740
Closed Access | Times Cited: 29
Blastic Plasmacytoid Dendritic Cell Neoplasm
Daniel Kerr, Ling Zhang, Lubomir Sokol
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 1
Closed Access | Times Cited: 35
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study
Marie‐Charlotte Brüggen, Julia Valencak, R. Stranzenbach, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 7, pp. 1489-1495
Open Access | Times Cited: 23
The advances in therapy of blastic plasmacytoid dendritic cell neoplasm
Daniel Kerr, Lubomir Sokol
Expert Opinion on Investigational Drugs (2018) Vol. 27, Iss. 9, pp. 733-739
Closed Access | Times Cited: 22
Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: A retrospective study in the Surveillance, Epidemiology, and End Results database
Xiao-Jing Lin, Li Wang, Qian Hu, et al.
European Journal Of Haematology (2023) Vol. 110, Iss. 6, pp. 743-753
Closed Access | Times Cited: 5
Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report
Katrine Fladeland Iversen, Paw Christian Holdgaard, Birgitte Preiss, et al.
Haematologica (2019) Vol. 104, Iss. 9, pp. e432-e433
Open Access | Times Cited: 15
A case series of blastic plasmacytoid dendritic cell neoplasia
Valentina Giudice
Translational Medicine UniSa (2020) Vol. 23, Iss. 4
Open Access | Times Cited: 12
Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia
Abdul Moiz Khan, Ayesha Munir, Mihir Raval, et al.
BMJ Case Reports (2019) Vol. 12, Iss. 7, pp. e230332-e230332
Open Access | Times Cited: 11
Modelling the Host Immune Response to Mature and Immature Dengue Viruses
Milen Borisov, Gabriel Dimitriu, Peter Rashkov
Bulletin of Mathematical Biology (2019) Vol. 81, Iss. 12, pp. 4951-4976
Closed Access | Times Cited: 10
Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study
Lifang Huang, Fan Wang
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Diabetic ketoacidosis following PEG-asparaginase therapy
Miriam Hinaa Ahmad, Ismat Shafiq
Endocrinology Diabetes and Metabolism Case Reports (2018) Vol. 2018
Open Access | Times Cited: 8
Venetoclax and Azacitidine in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory to Conventional Therapy
Farhan Azad, Jiahua Zhang, Clive J. Miranda, et al.
Cureus (2022)
Open Access | Times Cited: 5
Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study
Yue Lü, Ruijuan Sun, Jianping Zhang, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 13, pp. 3092-3099
Closed Access | Times Cited: 4
Cladribine‐based salvage regimen‐induced deep remission of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in leukemia phase
Han Yao, Peiyan Kong
Hematological Oncology (2020) Vol. 38, Iss. 2, pp. 207-209
Closed Access | Times Cited: 4
Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Nathaniel R. Wilson, Naveen Pemmaraju
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 4, pp. 431-438
Closed Access | Times Cited: 3
A Case Series of Blastic Plasmacytoid Dendritic Cell Neoplasia.
Bianca Serio, Valentina Giudice, Matteo D’Addona, et al.
PubMed (2020) Vol. 23, pp. 63-66
Open Access | Times Cited: 1
Primary Blastic Plasmacytoid Dendritic Cell Neoplasm: a US Population-Based Study
Fan Wang
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Blastic Plasmacytoid Dendritic Cell Neoplasm: Challenges in Diagnosis and Treatment with Potential of Venetoclax as an Alternative to Vincristine in High-Risk Patients-A case report
Naveed Syed, Waed Jaber, Islam Elkonaissi, et al.
Research Square (Research Square) (2023)
Open Access
Blastic plasmacytoid dendritic cell neoplasm: challenges in diagnosis and treatment with potential of venetoclax as an alternative to vincristine in high-risk patients—a case report
Naveed Syed, Waed Jaber, Islam Elkonaissi, et al.
Bulletin of the National Research Centre/Bulletin of the National Research Center (2023) Vol. 47, Iss. 1
Open Access
Patients with blastic plasmacytoid dendritic cell neoplasm in pregnancy: A rare case report
Li Zhang, Yidong Wang, Mingming Lu, et al.
Medicine (2022) Vol. 101, Iss. 38, pp. e30622-e30622
Open Access
Page 1

Scroll to top